Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study

The Lancet Infectious Diseases

Volumn 17, Issue 3, 2017, Pages 339-347

  Leung, Kathy ^a   Lipsitch, Marc ^c   Yuen, Kwok Yung ^b   Wu, Joseph T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; VIRAL PROTEIN;

ANTIVIRAL RESISTANT INFLUENZA STRAIN; ARTICLE; EPIDEMIC; FITNESS; HUMAN; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA VIRUS; INFORMATION; JAPAN; MATHEMATICAL MODEL; MONITORING; PANDEMIC; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS STRAIN; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GLOBAL HEALTH; INFLUENZA, HUMAN; THEORETICAL MODEL; TRANSMISSION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; EPIDEMICS; GLOBAL HEALTH; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MODELS, THEORETICAL; OSELTAMIVIR; RETROSPECTIVE STUDIES; VIRAL PROTEINS;

EID: 85007448625     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30465-0     Document Type: Article

References (30)

1. 1 WHO. WHO guidelines for pharmacological management of pandemic (H1N1) 2009: influenza and other influenza viruses, 2009, World Health Organization, Geneva.
2. 2 National Audit Office. Access to clinical trial information and the stockpiling of Tamiflu, 2013, National Audit Office, London, UK https://www.nao.org.uk/wp-content/uploads/2013/05/10155-001_Access-to-clinical-trial-info-and-the-stockpiling-ofTamiflu_21-May.pdf (accessed May 18, 2016).
3. 3 Ives, J, Carr, J, Mendel, D, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55 (2002), 307–317.
4. 4 Meijer, A, Lackenby, A, Hungnes, O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg Infect Dis, 15, 2009, 552.
5. 5 Kramarz, P, Monnet, D, Nicoll, A, Yilmaz, C, Ciancio, B, Use of oseltamivir in 12 European countries between 2002 and 2007—lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 14 (2009), 854–858.
6. 6 Stilianakis, NI, Perelson, AS, Hayden, FG, Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 177 (1998), 863–873.
7. 7 Wu, JT, Leung, GM, Lipsitch, M, Cooper, BS, Riley, S, Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med, 6, 2009, e1000085.
8. 8 Takashita, E, Meijer, A, Lackenby, A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antiviral Res 117 (2015), 27–38.
9. 9 Wu, WL, Lau, S-Y, Chen, Y, et al. The 2008–2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Res 93 (2012), 144–153.
10. 10 Mossong, J, Hens, N, Jit, M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med, 5, 2008, e74.
11. 11 Wu, JT, Ho, A, Ma, ESK, et al. Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med, 8, 2011, e1001103.
12. 12 Chunara, R, Aman, S, Smolinski, M, Brownstein, JS, Flu near you: an online self-reported influenza surveillance system in the USA. J Public Health Inform, 5, 2012, e133.
13. 13 Wong, JY, Wu, P, Nishiura, H, et al. Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong. Am J Epidemiol 177 (2013), 834–840.
14. 14 Vink, MA, Bootsma, MCJ, Wallinga, J, Serial intervals of respiratory infectious diseases: a systematic review and analysis. Am J Epidemiol 180 (2014), 865–875.
15. 15 Hurt, AC, Hardie, K, Wilson, NJ, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206 (2012), 148–157.
16. 16 Takashita, E, Kiso, M, Fujisaki, S, et al. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014 influenza season in Japan. Antimicrob Agents Chemother 59 (2015), 2607–2617.
17. 17 Govorkova, EA, Baranovich, T, Seiler, P, et al. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002–2012 shows need for continued monitoring. Antiviral Res 98 (2013), 297–304.
18. 18 Hai, R, Schmolke, M, Leyva-Grado, VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun, 4, 2013, 2854.
19. 19 Lipsitch, M, Cohen, T, Murray, M, Levin, BR, Antiviral resistance and the control of pandemic influenza. PLoS Med, 4, 2007, e15.
20. 20 McCaw, JM, Wood, JG, McCaw, CT, McVernon, J, Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS One, 3, 2008, 2362.
21. 21 Alexander, ME, Bowman, CS, Feng, Z, et al. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc Biol Sci 274 (2007), 1675–1684.
22. 22 Halloran, ME, Hayden, FG, Yang, Y, Longini, IM, Monto, AS, Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 165 (2007), 212–221.
23. 23 Wu, JT, Lee, CK, Cowling, BJ, Yuen, KY, Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proc Natl Acad Sci USA 107 (2010), 3269–3274.
24. 24 WHO. Influenza A(H1N1) virus resistance to oseltamivir, 2008, World Health Organization, Geneva http://www.who.int/influenza/patient_care/antivirals/oseltamivir_summary/en/ (accessed May 18, 2016).
25. 25 Tashiro, M, McKimm-Breschkin, JL, Saito, T, et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. Antivir Ther 14 (2009), 751–761.
26. 26 Wu, JT, Leung, K, Perera, RAPM, et al. Inferring influenza infection attack rate from seroprevalence data. PLoS Pathog, 10, 2014, e1004054.
27. 27 WHO. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses. Geneva: World Health Organization. http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/en/ (accessed May 18, 2016).
28. 28 Bloom, JD, Gong, LI, Baltimore, D, Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328 (2010), 1272–1275.
29. 29 Chao, DL, Bloom, JD, Kochin, BF, Antia, R, Longini, IM, The global spread of drug-resistant influenza. J R Soc Interface 9 (2012), 648–656.
30. 30 McCaw, JM, McVernon, J, Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic. Math Biosci 209 (2007), 336–360.